The Labelling of All Medicinal Products as Dependent on Animal Research would be a Minefield to be Avoided at All Costs

Abstract

The Medicinal Labelling Bill should be rejected by Parliament, as ill-conceived and an unworthy and transparent attempt to promote laboratory animal experimentation

Get full access to this article

View all access options for this article.

References

Anon. (2011). Animals: Experimentation. Question for Short Debate. Lords Hansard Text for 24 October 2011, columns 618–633. London, UK: Parliament UK. Available at: http://www.publications.parliament.uk/pa/ld201011/ldhansrd/text/111024-0002.htm (Accessed 28.10.13).

Balls

(2011). Animal experimentation and the labelling of drugs. ATLA 39, 497–500.

Anon. (2013). Medicinal Labelling Bill [HL]. London, UK: Parliament UK. Available at: http://www.publications.parliament.uk/pa/bills/lbill/2013-2014/0011/14011.pdf (Accessed 28.10.13).

Anon. (2013). Medicinal Labelling Bill [HL]. Second Reading. Lords Hansard Text for 25 October 2013, columns 1296–1310. London, UK: Parliament UK. Available at: http://www.publications.parliament.uk/pa/ld201314/ldhansrd/index/131025.html (Accessed 28.10.13).

Balls

(1991). Comments on labelling related to the animal testing of cosmetic ingredients and products manufactured and/or marketed within the European Economic Community. ATLA 19, 237–244.

Anon. (2013). This House would not ban all forms of animal research. London, UK: Understanding Animal Research. Available at: http://www.understandinganimalresearch.org.uk/news/2013/10/this-house-would-not-ban-all-forms-of-animal-research/ (Accessed 28.10.13).

Marx

, Walles

, Hoffmann

, Lindner

, Horland

, Sonntag

, Klotzbach

, Sakharov

, Tonevitsky

& Lauster

(2012). ‘Human-on-a-chip’ developments: A translational cutting-edge alternative to systemic safety assessment and efficiency evaluation of substances in laboratory animals and man? ATLA 40, 235–257.

Bailey

, Thew

& Balls

(2013). An analysis of the use of dogs in predicting human toxicology and drug safety. ATLA 41, 335–350.